Abstract 5015
Background
Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers in china. Because the disease often has no symptoms in the early stages, it is usually detected at a more advanced stage that is more challenging to treat. The inter-communication between esophageal squamous cell carcinoma and its surrounding microenvironment is essential for tumor progression and metastasis. Exosome plays a key role in information delivery between primary lesion and pre-metastatic niche via its packed bioactive molecules. The aim of this study is to explore the effect of exosome from tumor plasma to angiogenesis in human lymphatic endothelial cells (HLEC) in vitro.
Methods
Total circulation exosomes (CEs) were extracted and purified to selectively capture EpCAM positive exosomes by magnetic-bead technique. Proteins were separated by SDS-PAGE, and protein bands were analyzed by mass spectrometry. Tube formation assay and fluorescence imaging assay were performed in vitro.
Results
The expression level of CEs in ESCC patients with lymph node metastasis were significantly higher than that in ESCC patients without metastasis and healthy control group (respectively; P < 0.001). The tumor associated exosomes could be taken by HLEC and its transferred into HLECs could to promote HLECs tube formation in vitro. In addition, the mass spectrometry was used to analysis the proteomic content in tumor associated exosomes, tumor-related proteins such as matrix-metalloproteinases, PP2A proteins and EIF proteins were identified in the exosome.
Conclusions
Exosomes released by ESCC may play important roles in the microenvironment of ESCC and provide a potential application of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
NSFC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1851 - Nivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer: a multicenter real world analysis of 669 patients
Presenter: Nobuaki Mamesaya
Session: Poster Display session 1
Resources:
Abstract
851 - Retrospective analysis of immunotherapy prognostic scores in advanced NSCLC at Nottingham University Hospitals (UK)
Presenter: Cristina Lopez Escola
Session: Poster Display session 1
Resources:
Abstract
3639 - Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC)
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 1
Resources:
Abstract
2950 - Delayed Onset Immune Related Adverse Effects (IRAEs) of Pembrolizumab in Non-Small Cell Lung Cancer
Presenter: Haixi Yan
Session: Poster Display session 1
Resources:
Abstract
3659 - Clinical implication of multiplex IHC and serologic biomarkers on Hyperprogression in NSCLC patients receiving Immune checkpoint blockers in real world.
Presenter: Joori Kim
Session: Poster Display session 1
Resources:
Abstract
4882 - Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumor response to anti-PD1 treatment
Presenter: Florian Guisier
Session: Poster Display session 1
Resources:
Abstract
1358 - Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract
2170 - Prognostic Impact of Metastatic Sites for Pembrolizumab Efficacy as First-line therapy in Patients with PD-L1 tumor proportion score (TPS) ≥ 50% Advanced Non–Small Cell Lung Cancer: A Retrospective Multicenter Study
Presenter: Hayato Kawachi
Session: Poster Display session 1
Resources:
Abstract
3051 - Impact of visceral fat area as independent predictive factor in patients with advanced non-small cell lung cancer treated with nivolumab
Presenter: Yuki Sato
Session: Poster Display session 1
Resources:
Abstract
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract